NASDAQ:VCYT

Veracyte (VCYT) Stock Forecast, Price & News

$26.72

+0.53 (+2.02%)

(As of 06/2/2023 ET)

Compare

Today's Range: $26.12
▼
$26.96
50-Day Range: $20.58
▼
$26.72
52-Week Range: $14.92
▼
$32.40

Volume: 526,473 shs
Average Volume: 612,483 shs
Market Capitalization: $1.93 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.20

Veracyte MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 13.0% Upside
$30.20 Price Target
Short Interest: Bearish
5.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.01
Upright™ Environmental Score
News Sentiment: 0.58
Based on 7 Articles This Week
Insider Trading: Selling Shares
$1.56 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.55) to ($0.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

816th out of 983 stocks

Medical Laboratories Industry

19th out of 22 stocks

2.3

Analyst's Opinion

Consensus Rating
Veracyte has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $30.20, Veracyte has a forecasted upside of 13.0% from its current price of $26.72.
Amount of Analyst Coverage
Veracyte has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.15% of the outstanding shares of Veracyte have been sold short.
Short Interest Ratio / Days to Cover
Veracyte has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Veracyte has recently increased by 0.81%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Veracyte does not currently pay a dividend.
Dividend Growth
Veracyte does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Veracyte has received a 68.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Genomics analysis tools", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Veracyte is -1.01.

2.5

News and Social Media Coverage

News Sentiment
Veracyte has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Veracyte this week, compared to 3 articles on an average week.
Search Interest
3 people have searched for VCYT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,563,075.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Veracyte is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Veracyte are expected to grow in the coming year, from ($0.55) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veracyte is -65.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veracyte is -65.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veracyte has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

June 3, 2023 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Receives $31.00 Consensus Price Target from Analysts

May 30, 2023 | finance.yahoo.com

Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors

June 4, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 25, 2023 | benzinga.com

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte's Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

May 24, 2023 | finance.yahoo.com

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

May 22, 2023 | finance.yahoo.com

Here's Why This Little-Known Growth Stock Is a Buy

May 19, 2023 | americanbankingnews.com

Veracyte (NASDAQ:VCYT) Coverage Initiated by Analysts at StockNews.com

May 17, 2023 | msn.com

Looking Into Veracyte's Return On Capital Employed

June 4, 2023 | Legacy Research (Affiliate) (Ad)

From -60% Account to Doubling His Money?

After helping his readers double their money 13 TIMES in the last year alone… There’s ONE person trader Jeff Clark has NOT been able to help! His 23-year-old son, Grant.

May 16, 2023 | seekingalpha.com

Veracyte: Investing In The Future Of Genomic Diagnostics

May 11, 2023 | americanbankingnews.com

Analysts Set Veracyte, Inc. (NASDAQ:VCYT) PT at $31.00

May 10, 2023 | theglobeandmail.com

A New Groundbreaking Tool to Detect Colon Cancer Earlier

May 10, 2023 | msn.com

Stephens & Co. Reiterates Veracyte (VCYT) Overweight Recommendation

May 5, 2023 | finance.yahoo.com

Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript

May 4, 2023 | seekingalpha.com

Veracyte, Inc. 2023 Q1 - Results - Earnings Call Presentation

May 4, 2023 | finance.yahoo.com

Veracyte Announces First Quarter 2023 Financial Results

May 3, 2023 | finance.yahoo.com

Veracyte Announces Release of Inaugural ESG Report

May 3, 2023 | americanbankingnews.com

Veracyte (VCYT) to Release Quarterly Earnings on Thursday

May 1, 2023 | finance.yahoo.com

Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

May 1, 2023 | benzinga.com

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier

April 28, 2023 | venturebeat.com

Acuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of Directors

April 28, 2023 | nasdaq.com

Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?

April 27, 2023 | finance.yahoo.com

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

April 21, 2023 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Director Sells $749,360.00 in Stock

April 18, 2023 | finance.yahoo.com

The five-year returns have been strong for Veracyte (NASDAQ:VCYT) shareholders despite underlying losses increasing

April 16, 2023 | thestreet.com

Veracyte Dips After CMS Proposes Reimbursement Rate Reduction

April 15, 2023 | money.usnews.com

Veracyte Inc

See More Headlines

VCYT Price History

30 days | 90 days | 365 days | Advanced Chart

VCYT Company Calendar

Last Earnings: 5/04/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VCYT
CUSIP: N/A
CIK: 1384101
Web: www.veracyte.com
Phone: (650) 243-6300
Fax: 650-243-6301
Employees: 761
Year Founded: 2006

Price Target and Rating

Average Stock Price Forecast: $30.20
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +13.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,560,000.00
Net Margins: -9.70%
Pretax Margin: -9.66%
Return on Equity: -2.83%
Return on Assets: -2.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.49
Quick Ratio: 4.25

Sales & Book Value

Annual Sales: $296.54 million
Price / Sales: 6.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.93 per share
Price / Book: 1.79

Miscellaneous

Outstanding Shares: 72,420,000
Free Float: 70,317,000
Market Cap: $1.94 billion
Optionable: Optionable
Beta: 1.38

Social Links

Key Executives

Marc A. Stapley
Chief Executive Officer & Director

Rebecca Chambers
Chief Financial Officer

Richard T. Kloos
Executive Medical Director

Steven French
Chief Information Officer & Senior Vice President

Robert Brainin
Chief Business Officer & Executive Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.
What is Veracyte's stock price forecast for 2023?: 6 Wall Street research analysts have issued 1 year target prices for Veracyte's shares. Their VCYT share price forecasts range from $22.00 to $35.00. On average, they predict the company's stock price to reach $30.20 in the next twelve months. This suggests a possible upside of 13.0% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.
How have VCYT shares performed in 2023?: Veracyte's stock was trading at $23.73 at the start of the year. Since then, VCYT stock has increased by 12.6% and is now trading at $26.72.
View the best growth stocks for 2023 here.
When is Veracyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our VCYT earnings forecast.
How were Veracyte's earnings last quarter?: Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The biotechnology company earned $82.40 million during the quarter, compared to analyst estimates of $75.75 million. Veracyte had a negative trailing twelve-month return on equity of 2.83% and a negative net margin of 9.70%. Veracyte's revenue was up 21.5% compared to the same quarter last year. During the same period last year, the business posted ($0.20) EPS.
What ETFs hold Veracyte's stock?: ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Telemedicine & Digital Health ETF (EDOC), ARK Innovation ETF (ARKK), ARK Next Generation Internation ETF (ARKW), ROBO Global Artificial Intelligence ETF (THNQ) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).
What guidance has Veracyte issued on next quarter's earnings?: Veracyte issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $330.00 million-$340.00 million, compared to the consensus revenue estimate of $330.51 million.
What other stocks do shareholders of Veracyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?: Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
Who are Veracyte's major shareholders?: Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.66%), Wellington Management Group LLP (9.87%), BlackRock Inc. (9.12%), State Street Corp (5.76%), Artisan Partners Limited Partnership (5.01%) and Sumitomo Mitsui Trust Holdings Inc. (4.57%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho, Muna Bhanji and Robert S Epstein.
View institutional ownership trends.
How do I buy shares of Veracyte?: Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Veracyte's stock price today?: One share of VCYT stock can currently be purchased for approximately $26.72.
How much money does Veracyte make?: Veracyte (NASDAQ:VCYT) has a market capitalization of $1.94 billion and generates $296.54 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.
How many employees does Veracyte have?: The company employs 761 workers across the globe.
Does Veracyte have any subsidiaries?: The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
How can I contact Veracyte?: Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial